Barry Ticho Sells 7,176 Shares of Stoke Therapeutics (NASDAQ:STOK) Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK) insider Barry Ticho sold 7,176 shares of the business’s stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $29.04, for a total value of $208,391.04. Following the completion of the transaction, the insider owned 20,422 shares in the company, valued at approximately $593,054.88. This trade represents a 26.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Barry Ticho also recently made the following trade(s):

• On Monday, June 1st, Barry Ticho sold 1,795 shares of Stoke Therapeutics stock. The shares were sold at an average price of $30.58, for a total value of $54,891.10.

Stoke Therapeutics Price Performance

STOK stock opened at $31.93 on Friday. The stock’s 50 day moving average is $30.41 and its two-hundred day moving average is $32.05. Stoke Therapeutics, Inc. has a 52-week low of $12.86 and a 52-week high of $40.22. The company has a market capitalization of $2.06 billion, a PE ratio of -9.56 and a beta of 1.20.

Stoke Therapeutics (NASDAQ:STOK) last released its earnings results on Monday, August 3rd. The company reported ($0.93) EPS for the quarter, missing the consensus estimate of ($0.80) by ($0.13). Stoke Therapeutics had a negative net margin of 753.60% and a negative return on equity of 59.36%. The business had revenue of $9.32 million for the quarter, compared to analysts’ expectations of $4.89 million. As a group, sell-side analysts anticipate that Stoke Therapeutics, Inc. will post -3.41 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the stock. Canaccord Genuity Group decreased their price objective on shares of Stoke Therapeutics from $60.00 to $58.00 and set a “buy” rating for the company in a report on Tuesday. Wedbush increased their price target on shares of Stoke Therapeutics from $38.00 to $40.00 and gave the stock an “outperform” rating in a research report on Tuesday. The Goldman Sachs Group assumed coverage on Stoke Therapeutics in a research note on Monday, July 13th. They issued a “buy” rating and a $44.00 price target for the company. Guggenheim reissued a “buy” rating and issued a $60.00 price objective on shares of Stoke Therapeutics in a report on Tuesday. Finally, Chardan Capital reissued a “buy” rating and issued a $35.00 price objective on shares of Stoke Therapeutics in a report on Tuesday. Nine investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Stoke Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $43.00.

Institutional Trading of Stoke Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. RTW Investments LP lifted its position in shares of Stoke Therapeutics by 8.3% in the 4th quarter. RTW Investments LP now owns 5,546,856 shares of the company’s stock worth $176,057,000 after buying an additional 423,331 shares during the last quarter. Redmile Group LLC grew its position in shares of Stoke Therapeutics by 3.2% during the 1st quarter. Redmile Group LLC now owns 4,164,120 shares of the company’s stock valued at $135,584,000 after buying an additional 130,050 shares during the last quarter. Morgan Stanley grew its position in shares of Stoke Therapeutics by 0.3% during the 4th quarter. Morgan Stanley now owns 3,546,158 shares of the company’s stock valued at $112,555,000 after buying an additional 9,108 shares during the last quarter. State Street Corp raised its stake in Stoke Therapeutics by 75.2% during the fourth quarter. State Street Corp now owns 2,498,049 shares of the company’s stock worth $79,288,000 after acquiring an additional 1,072,176 shares during the period. Finally, BVF Inc. IL raised its stake in Stoke Therapeutics by 36.7% during the fourth quarter. BVF Inc. IL now owns 2,265,674 shares of the company’s stock worth $71,912,000 after acquiring an additional 608,578 shares during the period.

Key Stoke Therapeutics News

Here are the key news stories impacting Stoke Therapeutics this week:

• Positive Sentiment: Wedbush raised its price target to $40 and maintained an “outperform” rating, while Chardan Capital reiterated “buy” with a $35 target. Canaccord retained a “buy” rating despite lowering its target to $58. The broader analyst consensus remains “Moderate Buy,” with an average target of $43. Wedbush price-target update
• Positive Sentiment: Investors continue to focus on Stoke’s pipeline. Management plans to submit a rolling NDA for zorevunersen in the first quarter of 2027 for SCN1A-related Dravet syndrome, while continuing development of STK-002. Approximately $420 million in cash could support these programs and potential launch preparations. Pipeline and NDA outlook
• Neutral Sentiment: Stoke is scheduled to present at the Canaccord Genuity 46th Annual Growth Conference, giving management an opportunity to provide updates on its clinical and regulatory plans. Conference presentation announcement
• Negative Sentiment: HC Wainwright cut its EPS forecasts across 2026–2028: FY2026 to a loss of $3.35 per share from $3.09, FY2027 to a loss of $2.55 from $2.05, and FY2028 to a loss of $1.78 from $0.67. It also lowered quarterly estimates to losses of $0.81 per share. These revisions point to slower progress toward profitability. HC Wainwright earnings estimates
• Negative Sentiment: Stoke’s second-quarter loss of $0.93 per share exceeded the expected loss of $0.80, although revenue of approximately $9.33 million surpassed estimates. The company remains deeply unprofitable, increasing investor sensitivity to cash use and development execution. Second-quarter earnings summary
• Negative Sentiment: Director Barry Ticho sold 7,176 shares for approximately $208,000, reducing his stake by 26%. The sale was conducted under a pre-arranged Rule 10b5-1 plan, which limits its significance but may still weigh modestly on sentiment. SEC insider-sale filing

About Stoke Therapeutics

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.